Skip to main content
main-content

01.12.2012 | Letter to the Editor | Ausgabe 1/2012 Open Access

Journal of Hematology & Oncology 1/2012

The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis

Zeitschrift:
Journal of Hematology & Oncology > Ausgabe 1/2012
Autoren:
Li-Juan Zhang, Ji Xu, Peng Liu, Chong-Yang Ding, Jian-Yong Li, Hong-Xia Qiu, Su-Jiang Zhang
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1756-8722-5-40) contains supplementary material, which is available to authorized users.
Li-Juan Zhang, Ji Xu contributed equally to this work.

To the Editor

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a hyper-inflammatory clinical syndrome mainly caused by severe infections, autoimmune inflammatory disorders and malignancies, especially lymphoma [13]. Up to date, very few data from the literature are available regarding the role of 18F-FDG PET/CT in sHLH. In this study, 18 of 50 patients with sHLH who were admitted into our hospital between May 2007 and December 2010 underwent the examination (Table 1). The male-to-female ratio was 1:1, and the median age was 35 years (15-73). The diagnosis of HLH was made according to HLH-2004 diagnostic guidelines [4, 5], and the underlying diseases were confirmed by a series of pathogenesis examinations including pathology, immunology, bacterial culture and virus detection et al. The maximum standardized uptake values (SUVmax) used to measure the level of FDG uptake were determined in all lesions [6]. All of the 18 patients had at least 3 organs involved, with increased FDG uptake at different level, including 18 cases showing splenomegaly, 16 cases serous effusions, 16 cases lymphadenopathy, 13 cases bone lesions, 12 cases pneumonia, 8 cases hepatomegaly, 5 cases brain parenchymal or cerebroventricular lesions, 5 cases cholecystitis, 4 cases myocardium lesions, and 2 cases kidney calculi. There were also other organs involved, such as larynx, muscles and adnexauteri. Fifteen patients (15/18) had definite underlying diseases, and were divided into three groups.,including Infection Associated HLH (IAHLH, including EBV-HLH, n = 8), Rheumatosis Associated HLH (RAHLH, n = 2), and Malignancy Associated HLH (MAHLH, n = 5). The SUVmax of patients in MAHLH group was significantly higher than those of patients with IAHLH (Mean 12.0 vs. 6.8, P = 0.015), and RAHLH (Mean 12.0 vs. 2.7, P = 0.045). Furthermore, the SUVmax of patients with IAHLH was significantly higher than that of patients with RAHLH (Mean 6.8 vs. 2.7, P = 0.043). However, no significant difference in survival time was found between the three different sHLH subtype according to Kaplan-Meier analysis (P >0.05). In conclusion, 18F-FDG PET/CT may play important role in differential diagnosis of sHLH, with high SUV pointing toward underlying malignancy.
Table 1
Characteristics of 18 sHLH patients
No.
Age/ Sex
Underlying disease
Therapy
Outcome
Survival (month)
Organs
SUVmax
1
35/M
Lymphoma (NK / T)
IVIG/HLH-2004 regimen(1 cycle) → High-dose methylprednisolone pulse therapy
Died of intracranial hemorrhage
1.7
6
12.3
2
35/F
Lymphoma (NK / T)
The Hyper-CVAD regimen (1 cycle)
Died of intracranial hemorrhage
1.2
6
15.7
3
18/M
Lymphoma (NK / T)
The CHOP regimen(1 cycle)
Died of acute hemorrhage of gastrointestinal tract
0.3
7
14.6
4
56/M
Lymphoma
Hydrocortisone 100mg×5d
Died of intracranial hemorrhage
1.7
5
4.3
5
32/M
Lymphoma
Dex 10mg/d×3d
Died of liver failure
0.3
10
13.3
6
37/F
Sjögren's syndrome
The COP regimen(3 cycle)
CR
>12
5
0.7
7
15/F
UCTD
The COP regimen (4 cycle)
CR
>45
3
4.6
8
21/F
EBV infection
HLH-2004 regimen (1 cycle)
Died of acute hemorrhage of gastrointestinal tract
1.7
7
6.6
9
17/M
EBV infection
Methylprednisolone 40 mg/d×24d
CR
>22
7
8.3
10
46/M
EBV infection
Dex 15mg/d×4d
Died of septic shock
0.4
6
10
11
73/M
EBV infection
The COP regimen (7 cycle)
Died of multi-organ failure
6
7
5.2
12
26/F
CMV infection
IVIG/HLH-2004 regimen (1 cycle) →The CHOP regimen(2 cycle)
CR
>24
6
9
13
24/F
CMV infection
The COP regimen (7 cycle)
Died of respiratory failure
2.2
5
4.2
14
69/F
MRSH infection
The COP regimen (2 cycle)
Died of respiratory failure
2.0
6
5.2
15
62/F
Fungal Infection
The COP regimen (7 cycle)
stable
>8
4
5.8
16
44/F
Malignant tumour?
Methylprednisolone 40 mg/d×5d
Died of multi-organ failure
0.4
8
7.7
17
56/M
Lymphoma?
The CHOP regimen (2 cycle) →Splenectomy→The Hyper-CVAD regimen (1cycle)
stable
>13
6
5.7
18
18/M
indefinite
HLH-2004 regimen (1 cycle)
Died of intracranial hemorrhage
0.2
3
4.2
HLH-2004, dexamethasone, etopside and Ciclosporin A; CHOP, cyclophosphamide, adviamycin, vincristine and prednisolone; COP, cyclophosphamide, vincristine and prednisone; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine; DEX, dexamethasone; CR, complete response; UCTD, undifferentiated connective tissue disease; EBV, Epstein-Barr virus; CMV, cytomegalovirus; MRSH, methicillin-resistant Staphylococcus hominis.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81070456, 81170490), ‘Liu Da Ren Cai Gao Feng’ of Jiangsu Province (2010-WS-019), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Zusatzmaterial
Authors’ original file for figure 1
13045_2012_231_MOESM1_ESM.jpeg
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Journal of Hematology & Oncology 1/2012 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise